PET/CT and PET/MRI in Cancer Diagnosis and Management: A Comparative Clinical Perspective
iMetaMed · 2026-06 · 2 (2)
DOI: 10.1002/imm3.70045 ↗Kurz gefasst
Fachartikel in der Zeitschrift iMetaMed, online erschienen am 22.06.2026. Verfasst von Zijian Ding und 5 weiteren Autor:innen. Die Arbeit nennt 372 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Positron emission tomography/computed tomography (PET/CT) and PET/magnetic resonance imaging (PET/MRI) have significantly advanced the field of oncologic imaging. This review presents a comparative evaluation of these hybrid modalities in terms of technical principles, image quality, radiation exposure, and diagnostic performance across a range of cancers, including lung, breast, prostate, and brain tumors. We discuss their respective strengths in anatomical and functional characterization, alongside emerging innovations such as artificial intelligence and ultra‐low dose protocols. Despite their growing clinical utility, challenges such as high cost, limited availability, and protocol standardization remain. Both PET/CT and PET/MRI play critical roles in cancer diagnosis and management, with ongoing developments offering further potential for clinical integration.
Zitieren
APA
Ding, Z., Xue, R., Jin, Q., Zhang, W., Wu, Y., & Xu, B. (2026). PET/CT and PET/MRI in Cancer Diagnosis and Management: A Comparative Clinical Perspective. iMetaMed, 2(2). https://doi.org/10.1002/imm3.70045
Vancouver
Ding Z, Xue R, Jin Q, Zhang W, Wu Y, Xu B. PET/CT and PET/MRI in Cancer Diagnosis and Management: A Comparative Clinical Perspective. iMetaMed. 2026;2(2). doi:10.1002/imm3.70045
BibTeX
@article{Ding2026,
author = {Ding, Zijian and Xue, Ran and Jin, Qianxi and Zhang, Wangzheqi and Wu, Yali and Xu, Baixuan},
title = {PET/CT and PET/MRI in Cancer Diagnosis and Management: A Comparative Clinical Perspective},
journal = {iMetaMed},
year = {2026},
volume = {2},
number = {2},
doi = {10.1002/imm3.70045}
}
EUVIMED